Key Highlights

  • The FDA extended the action date for Capricor Therapeutics (NASDAQ:CAPR) and its deramiocel application from August 22 to November 22, 2026 after classifying new data as a major amendment.
  • An FDA advisory committee voted 3 to 9 on July 29, 2026 on whether evidence showed substantial effectiveness for Duchenne cardiomyopathy, and the vote is advisory and non-binding.
  • Cash, equivalents and marketable securities were about USD 237.9 million at June 30, 2026, down from about USD 318.1 million at the end of 2025, with no Revenue recognized.
  • The second quarter net loss was about USD 40.7 million, or USD 0.70 per share, up from USD 25.9 million a year earlier.

The Review Narrows to Upper Limb Function

Capricor is a clinical-stage biotechnology company developing deramiocel, a cell therapy for Duchenne muscular dystrophy. The FDA issued a complete response letter in July 2025, then resumed review in March 2026 after the Phase 3 HOPE-3 results and set an August 22 date. On August 24, 2026, Capricor Therapeutics (NASDAQ:CAPR) announced that a submission including 24-month open-label extension data was treated as a major amendment, pushing the date to November 22, 2026. The company asked the agency to consider a refined indication centered on upper limb function, the primary endpoint of HOPE-3. The original review, which began under priority review in 2025, had focused on heart function.

Mixed Evidence and a Funding Clock

HOPE-3 met its primary upper limb endpoint, PUL 2.0, with a p-value of 0.029, and was published in The Lancet. However, a statistical model error moved the left ventricular ejection fraction result from a p-value of 0.04 to 0.09. The FDA also inspected the company in July 2026 and issued a Form 483 with one observation, to which Capricor responded. The company has said its cash covers at least 12 months, while spending ran at about USD 42.9 million in operating expenses in the second quarter, and launch preparations are moving more slowly until regulatory clarity improves.

Screen Growth Figure and Binary Risk

A screen listed Capricor as an aggressive small cap with a 48.91% one year EPS change and a price near USD 8.27, up 0.36%. Those are unconfirmed published market data. The company has no revenue and a widening loss, so any EPS improvement could reflect a small or odd base and could not be matched to a filing. The market cap was not verified. An FDA decision, a possible further delay, an arbitration with a distribution partner expected to begin this fall, and cash burn are the main risks to watch. Biotech shares can gap sharply on regulatory news in either direction, and a screen move of 0.36% says little about how the market will react to a decision. Investors may also look for the third quarter report and any update on the FDA's inspection feedback.

Where Things Stand

Capricor Therapeutics (NASDAQ:CAPR) can only get an answer by November 22, 2026 if the FDA acts on schedule, and the agency has already shown it can extend a date. The 3 to 9 panel vote was on cardiomyopathy and is not binding, while the amended filing leans on upper limb data that met its endpoint. Cash of about USD 237.9 million gives time, but the loss is widening and there is no product revenue. A decision, a delay, or another request for information are all possible outcomes.